

contacting NICEATM (see **FOR FURTHER INFORMATION CONTACT** above).

#### Attendance and Registration

In order to facilitate planning for this meeting, persons wishing to attend are asked to register by April 14, 2009, via the NICEATM–ICCVAM Web site ([http://iccvam.niehs.nih.gov/contact/reg\\_LLNAPanel.htm](http://iccvam.niehs.nih.gov/contact/reg_LLNAPanel.htm)). Visitor parking is located in the multi-level parking garage accessible via NIH Gateway Drive. All visitors should proceed to the Gateway Center to receive a visitor badge. Note: parking is limited and a government-issued ID is required for access (an area map, driving directions, and NIH contact information are available at <http://www.nih.gov/about/visitor/index.htm>).

#### Availability of the Revised Documents

The revised draft BRDs and revised draft ICCVAM test method recommendations will be available from the NICEATM–ICCVAM Web site ([http://iccvam.niehs.nih.gov/methods/immunotox/llna\\_PeerPanel.htm](http://iccvam.niehs.nih.gov/methods/immunotox/llna_PeerPanel.htm)) by March 3, 2009, or by contacting NICEATM (see **FOR FURTHER INFORMATION CONTACT** above).

#### Request for Public Comments

NICEATM invites the submission of written comments on the revised draft BRDs and revised draft ICCVAM test method recommendations and prefers that comments be submitted by April 14, 2009, electronically via the NICEATM–ICCVAM Web site [http://iccvam.niehs.nih.gov/contact/FR\\_publiccomment.htm](http://iccvam.niehs.nih.gov/contact/FR_publiccomment.htm) or via e-mail at [niceatm@niehs.nih.gov](mailto:niceatm@niehs.nih.gov). Written comments may also be sent by mail, fax, or e-mail to Dr. William Stokes, Director of NICEATM, at the address listed above (see **FOR FURTHER INFORMATION CONTACT**). When submitting written comments, please refer to this **Federal Register** notice and include appropriate contact information (name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization, if applicable). All comments received will be placed on the NICEATM–ICCVAM Web site (<http://iccvam.niehs.nih.gov>), and identified by the individual's name and affiliation or sponsoring organization (if applicable). Comments will also be provided to the Panel and ICCVAM agency representatives, and made available at the meeting.

Time will be provided for the presentation of oral comments by the public at designated times during the peer review. Members of the public who wish to present oral statements at the meeting (one speaker per organization) should contact NICEATM (see **FOR**

**FURTHER INFORMATION CONTACT** above) by April 14, 2009 and provide a written copy of their comments. Each speaker is asked to provide contact information (name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization, if applicable) when registering to make oral comments. Up to seven minutes will be allotted per speaker. If this is not possible, please bring 40 copies of your comments to the meeting for distribution and to supplement the record. Written statements can supplement and expand the oral presentation. Please provide NICEATM with copies of any supplementary written statement using the guidelines outlined above.

Summary minutes and the Panel's final report will be available following the meeting on the NICEATM–ICCVAM Web site (<http://iccvam.niehs.nih.gov>). ICCVAM will consider the Panel's conclusions and recommendations and any public comments received in finalizing their test method recommendations and performance standards for these methods.

#### Background Information on ICCVAM, NICEATM, and the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM)

ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that use, generate, or disseminate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological test methods that more accurately assess the safety and hazards of chemicals and products and that refine, reduce, and replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l–3) established ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of U.S. Federal agencies. Additional information about ICCVAM and NICEATM can be found on their Web site (<http://iccvam.niehs.nih.gov>).

SACATM was established January 9, 2002, and is composed of scientists from the public and private sectors (67 FR 11358). SACATM provides advice to the Director of the NIEHS, to ICCVAM, and to NICEATM regarding the statutorily-mandated duties of ICCVAM and activities of NICEATM. Additional

information about SACATM, including the charter, roster, and records of past meetings, can be found at <http://ntp.niehs.nih.gov/>; see “Advisory Board & Committees” (or directly at <http://ntp.niehs.nih.gov/go/167>).

Dated: February 19, 2009.

**John R. Bucher,**

*Associate Director, NTP.*

[FR Doc. E9–4280 Filed 2–26–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Unsolicited Multi-Project (P01) Grant Applications.

*Date:* March 20, 2009.

*Time:* 11 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700–B Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Roberta Binder, PhD, Scientific Review Officer, Division of Extramural Activities, NIAID, 6700B Rockledge Drive, Rm 2155, Bethesda, MD 20892, 301–496–7966, [rb169n@nih.gov](mailto:rb169n@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 20, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–4191 Filed 2–26–09; 8:45 am]

**BILLING CODE 4140–01–P**